IoM Committee To Hear CDER, PhRMA Perspectives On Drug Safety System
This article was originally published in The Pink Sheet Daily
Executive Summary
CDER Acting Director Galson will outline FDA's charge to the Institute of Medicine drug safety committee, while PhRMA Regulatory Affairs VP Goldhammer will discuss industry perspectives at the first meeting of the ad hoc committee June 8.